CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,185,695 | -39.3% | 588,143 | -25.1% | 1.37% | -38.5% |
| Q2 2023 | $26,660,158 | +7.4% | 785,740 | +13.9% | 2.23% | +28.8% |
| Q1 2023 | $24,814,542 | -0.4% | 689,676 | +23.4% | 1.73% | -20.7% |
| Q4 2022 | $24,904,557 | +41.4% | 558,774 | -10.8% | 2.18% | +42.9% |
| Q3 2022 | $17,607,317 | -18.8% | 626,372 | -22.1% | 1.53% | -1.0% |
| Q2 2022 | $21,691,692 | +0.1% | 804,588 | +26.4% | 1.54% | -7.4% |
| Q1 2022 | $21,677,589 | -5.3% | 636,453 | +7.4% | 1.66% | +13.9% |
| Q4 2021 | $22,893,350 | +925.8% | 592,478 | +293.7% | 1.46% | +194.8% |
| Q3 2020 | $2,231,826 | -75.9% | 150,494 | -78.9% | 0.50% | -60.9% |
| Q2 2020 | $9,265,074 | – | 712,698 | – | 1.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |